PPT-EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal. Colin Reisterer and Nick Swenson. S. . Maheswaran. et al. . The New England Journal of Medicine. . 2007. http://www.all-cancer-treatments.com/types-of-lung-cancer.html. Clinical background: Non-small cell lung cancer (NSCLC). Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. The Role of Antiangiogenic Agents in the Changing Treatment Paradigm of NSCLC: Expert Perspectives Moderator Solange Peters, MD, PhD Chair, Medical Oncology Department of Oncology Centre Hospitalier Universitaire Vaudois (CHUV) Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. LAB 2. Some Drugs That Effect CNS. Stimulants. Depressants. A . stimulant. is a drug that speeds up activities of the CNS. A . depressant. . is a. . drug that slows brain and body reactions. Stimulants increase. Cécile Jovelet. Postdocoral. . fellow. Translational. . research. . lab. Gustave Roussy Institute, France. Introduction . 12/04/2017. 2. Lung cancer: . third most frequent cancer. Non-Small Cell Lung Cancer (NSCLC): 80% cases of lung cancer. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab . utama kematian akibat kanker . . Terdiagnosis pada stadium lanjut. Pembagian pasien kanker paru berdasarkan stadium di bangsal paru RSDM. Th. 2014 . Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .